PRESS RELEASE published on 08/17/2023 at 22:15, 2 years 3 months ago Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
PRESS RELEASE published on 08/03/2023 at 12:30, 2 years 4 months ago Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
PRESS RELEASE published on 07/13/2023 at 13:00, 2 years 4 months ago Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
PRESS RELEASE published on 07/05/2023 at 13:00, 2 years 5 months ago Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
PRESS RELEASE published on 07/03/2023 at 07:00, 2 years 5 months ago Moderna Submits Regulatory Application to the European Medicines Agency for Its Updated COVID-19 Vaccine
PRESS RELEASE published on 06/22/2023 at 22:05, 2 years 5 months ago Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine
PRESS RELEASE published on 06/05/2023 at 14:00, 2 years 6 months ago Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
PRESS RELEASE published on 06/01/2023 at 22:05, 2 years 6 months ago Moderna to Present at Upcoming Conferences in June 2023
PRESS RELEASE published on 05/30/2023 at 14:00, 2 years 6 months ago Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting
PRESS RELEASE published on 05/19/2023 at 13:00, 2 years 6 months ago Phase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA), Presented at the 2023 ASGCT Annual Meeting
Published on 12/05/2025 at 21:45, 42 minutes ago When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 57 minutes ago The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 1 hour 7 minutes ago Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Published on 12/05/2025 at 21:00, 1 hour 27 minutes ago The Repricing Event: Why Multiple Global Industries Are Suddenly Moving Toward SMX
Published on 12/05/2025 at 20:25, 2 hours 2 minutes ago The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 22:15, 12 minutes ago CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 15 minutes ago EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 3 hours 29 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 4 hours 12 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:18, 5 hours 9 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 5 hours 9 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 7 hours 16 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 7 hours 16 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 8 hours 29 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
